Results 231 to 240 of about 8,253,745 (359)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Retracted: Intravenous Leiomyoma with Extension to the Heart: A Case Report and Review of the Literature

Case Reports in Obstetrics and Gynecology, 2014
Case Reports in Obstetrics and Gynecology
doaj   +1 more source

State of the journal 2026: <i>Heart Rhythm Case Reports</i>. [PDF]

HeartRhythm Case Rep
Doshi R.
europepmc   +1 more source

Takayasu's arteritis presenting as bilateral cataracts: report of three cases [PDF]

, 2003
Luis‐Felipe Flores‐Suarèz
openalex   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Large renal arteriovenous fistula treated by embolization: 2 case reports. [PDF]

Radiol Case Rep
Vu DL, Vu ND, Tran VL, Do DT, Tran VG, Tran DH, Tu DN, Le HK.   +7 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Case reports from low‐ and middle‐income countries: supporting clinical evidence for those most in need

Clinical Case Reports, 2018
Angela Vinturache
doaj   +1 more source

Motivated

JACC: Case Reports, 2019
Julia Grapsa, MD, PhD
doaj   +1 more source

Editorial: Case reports in heart surgery 2024. [PDF]

Front Cardiovasc Med
Gatti G.
europepmc   +1 more source